More News

14 Jun 2022 Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
13 Jun 2022 ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
10 Jun 2022 Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
08 Jun 2022 Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
06 Jun 2022 Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
03 Jun 2022 Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
03 Jun 2022 Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies
03 Jun 2022 Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
02 Jun 2022 Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
02 Jun 2022 Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
01 Jun 2022 Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
31 May 2022 GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
24 May 2022 KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
23 May 2022 Innoviva to Acquire Entasis Therapeutics
20 May 2022 Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
19 May 2022 Almirall and Evotec enter into a multi-target alliance in Medical Dermatology
18 May 2022 BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen
17 May 2022 LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
16 May 2022 AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
16 May 2022 Remix Therapeutics Closes $70 Million Series B Financing
13 May 2022 BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
12 May 2022 Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
11 May 2022 Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
10 May 2022 Pfizer to Acquire Biohaven Pharmaceuticals
09 May 2022 Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up